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Abstract  Thermal  ablation  techniques  for  renal  tumours  have  become  the  norm  in  surgically
at-risk patients.  These  percutaneous  treatments  are  locally  effective,  particularly  for  tumours
measuring  less  than  4  cm.  Larger  tumours  may  be  treated  by  adapting  the  technique  and  strat-
egy. Multidisciplinary  discussion  is  essential  before  any  decision,  in  order  to  decide  on  the  most
appropriate  technique.  Radiofrequency  is  simple,  effective  and  inexpensive.  Cryotherapy  is
more complex  and  should  be  preferred  when  the  tumour  is  large  or  there  is  vascular  or  uri-
nary tract  contact.  Microwaves  can  be  used  to  treat  larger  tumours.  Morbidity  is  low,  but  good
knowledge  of  these  techniques  and  of  dissection  is  required  to  avoid  injury  to  neighbouring
digestive or  urinary  structures.
©  2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Over  the  last  few  decades,  the  increasing  use  of  imaging  in  many  diseases  has  profoundly
altered  the  natural  history  of  kidney  cancer.  Nearly  50%  of  kidney  cancers  diagnosed  are
currently  discovered  by  chance  [1].  This  has  meant  earlier  detection  of  often  small,  renal
tumours,  and  in  70  to  80%  of  cases,  while  they  are  still  in  a  non-metastatic  stage  [2,3].
These  changes  in  presentation  and  prognosis  have  considerably  modiﬁed  the  management
of  renal  cell  carcinomas  (RCC),  particularly  over  the  last  ten  years,  with  the  development
of  nephron-sparing  techniques  replacing  open  surgery.  The  initial  technique  of  laparo-
scopic  partial  nephrectomy  has  been  supplemented  by  the  techniques  of  laparoscopic
thermal  ablation,  including  the  use  of  radiofrequency  (RF)  and  cryoablation.  However,
some  patients  with  small  kidney  cancers  cannot  tolerate  a  surgical  procedure,  because  of
advanced  physiological  age,  comorbidities,  or  already  precarious  renal  function.  For  these
patients,  a  percutaneous  approach  using  thermal  ablation  is  gradually  predominating,
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particularly  because  the  equipment  and  techniques  have
developed  to  be  ever  more  efﬁcient  in  terms  of  sparing  renal
function  and  being  less  invasive  for  these  fragile  patients.
This  review  does  not  set  out  to  explain  the  principles  of
the  various  thermal  ablation  techniques  (RF,  cryoablation,
microwaves,  laser  and  focused  ultrasound),  already  widely
described  in  the  literature,  but  aims  rather  to  give  the  ben-
eﬁts,  limitations,  complications  and  performance  reported,
and  the  principles  of  post-treatment  monitoring.
Guidance methods
A  percutaneous  approach  is  required  in  the  majority  of
thermal  ablation  indications  and  techniques.  However,  the
laparoscopic  route,  which  is  effective  in  oncological  terms
[4],  is  still  suggested  for  tumours  at  risk  due  to  their
topography,  particularly  in  an  anterior  position  and  there-
fore  difﬁcult  to  access  via  a  posterior  approach,  justifying
direct  visual  control  during  thermal  ablation.  Apart  from
its  less  invasive  character,  the  advantages  of  the  percuta-
neous  approach  are  less  pain,  immediate  veriﬁcation,  which
is  possible  using  CT,  MRI  or  ultrasound,  a  shorter  period
of  hospitalisation  [5]  and  reduced  overall  cost  [6].  In  his
meta-analysis  of  46  studies  from  1996  to  2006,  Hui  et  al.  [5]
concluded  that  percutaneous  radiofrequency  is  safer  and  as
effective  as  laparoscopic  radiofrequency,  with  complication
rates  of  3.1  and  7.4%  respectively,  for  identical  secondary
efﬁcacy  of  92%  at  5  years.
CT  guidance  is  currently  best  for  localising  the  tumour
and  controlling  the  procedure.  The  limits  and  relationships
of  the  tumour  to  be  treated  can  be  precisely  deter-
mined,  but  nevertheless  it  can  be  adversely  affected  by  the
patient’s  breathing  movements,  which  justiﬁes  positioning
the  applicators  during  apnoea.  At  the  end  of  the  procedure,
it  can  help  in  looking  for  immediate  complications  before
the  patient  is  transferred  to  the  recovery  room.  However,
because  of  the  risks  of  using  iodinated  contrast  agents  and
the  frequent  need  for  an  injection  of  contrast  agent  before
thermal  ablation,  to  identify  the  relationships  of  the  lesion,
identifying  enhancement  of  tumour  remnants  at  the  end
of  the  session  can  be  difﬁcult.  This  may  prevent  any  fur-
ther  treatment  during  the  same  period  of  anaesthesia.  As
an  alternative,  or  associated  with  CT,  ultrasound  guidance
has  proved  to  be  feasible  and  to  provide  good  procedu-
ral  safety  [7,8]  and  can  be  an  effective  aid  for  fast  and
accurate  positioning  of  the  applicators.  It  is  nevertheless
limited  by  the  generally  narrow  acoustic  window;  in  the
same  way,  the  formation  of  hyperechoic  gas  microbubbles
at  the  treatment  site  alters  the  ultrasound  window  [9]  in
radiofrequency  therapy,  and  the  formation  of  ice  is  a  source
of  reﬂection  during  cryotherapy.  Finally,  MRI  guidance  pro-
vides  real-time  monitoring  of  the  ablation  site,  either  by
conventional  T1-weighted  sequences  with  or  without  con-
trast,  by  T2  sequences  or  by  thermometry  sequences  [9].
This  technique  is  however  limited  by  restricted  accessibility
and  MRI  compatible  equipment.Performing biopsies
At  the  time  when  surgery  was  the  only  therapeutic  option  for
a  solid  renal  mass,  biopsies  were  limited  to  lesions  suspected
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f  being  renal  metastases,  lymphomas  or  abscesses,  or
hen  histological  analysis  was  needed  because  of  metastatic
evelopment  of  a  cancer  or  tumour  which  could  not
e  immediately  resected  [10]. Heilbrun  argued  that  pre-
perative  biopsies  did  not  provide  additional  information  for
onﬁrming  the  malignancy  of  lesions  when  the  character-
stics  of  malignancy  were  typical  in  pre-operative  imaging
11].
When  thermal  ablation  treatment  is  to  be  undertaken,
n  the  other  hand,  pre-treatment  biopsy  seems  to  be  justi-
ed,  ﬁrstly  because  there  will  be  no  postoperative  surgical
pecimen,  secondly  because  nearly  20%  of  T1  tumours  are
stimated  to  be  benign  (particularly  when  less  than  3  cm
12], with  up  to  44%  of  tumours  less  than  1  cm  being  benign
13])  and  thirdly  because  of  the  value  of  grading  the  lesion
nd  obtaining  a  molecular  analysis  for  determining  a  prog-
osis.  This  is  all  the  more  justiﬁed  now  that  the  rate  of
alse-negative  biopsies  is  in  the  order  of  1%,  with  an  inci-
ence  of  symptomatic  complications  of  less  than  2%  [14].
n  certain  special  cases  (e.g.  von  Hippel  Lindau  disease,
 recent  history  of  RCC),  a  biopsy  is  not  essential.  Simi-
arly,  for  cystic  tumours,  the  risk  of  malignancy  can  currently
e  evaluated  using  Bosniak’s  classiﬁcation  and  the  resulting
herapeutic  choices  assessed  [2].
Two  approaches  should  be  discussed  if  it  is  decided  that
 biopsy  is  indicated.  A  biopsy  performed  during  the  same
ession  as  the  ablation  certainly  has  the  advantage  of  saving
ime  and  being  more  comfortable  for  the  patient.  However,
ue  to  the  signiﬁcant  proportion  of  biopsies  that  have  proved
egative  or  shown  a  benign  lesion  and  have  led  to  treat-
ent  without  any  histological  evidence  or  even  treatment
hat  was  unnecessary,  biopsy  is  now  proposed  during  a  pro-
edure  prior  to  thermal  ablation.  This  provides  a  sample
ontributing  to  the  decision  before  treatment  [15]  but  can
ut  constraints  on  patients  who  may  require  adjustment  to
heir  anticoagulant  or  antiplatelet  medication.
linical results
hermal ablation using radiofrequency
ince  Zlotta  et  al.  [16], many  studies  have  reported  the  efﬁ-
acy  of  radiofrequency  ablation  (Fig.  1)  on  RCC,  even  though
ong-term  studies  are  not  yet  available.  Local  recurrence-
ree  survival  at  5  years  is  in  the  order  of  89  to  92%  [17,18]
nd  most  authors  agree  on  the  fact  that  most  recurrences
ppear  during  the  ﬁrst  year  [19]. However,  recurrences  can
ccur  several  years  after  what  was  considered  to  have  been
omplete  treatment  of  the  lesion  [20], although  after  three
ears  they  are  still  rare  [21]. In  a  long-term  follow-up  of  a
ean  of  61.6  months  in  a  population  of  31  patients,  Levinson
escribes  only  three  in  situ  recurrences,  all  occurring  before
1  months,  and  no  metastatic  development  [22]. Primary
fﬁcacy  is  67  to  100%  [17—19,23].  This  wide  heterogene-
ty  of  results  can  be  explained  particularly  by  very  variable
ollow-up  times  and  tumour  sizes.  Nevertheless,  the  pro-
ortion  of  conversions  to  surgery  is  low,  with  a  mean  of
.6%  in  the  literature,  because  repeating  radiofrequency
rocedures  is  not  described  as  a  technical  challenge;  it
s  used  in  a  mean  of  8.5%  of  cases  [24]. The  secondary
fﬁcacy  of  radiofrequency  treatment  seems  much  more
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Figure 1. Radiofrequency thermal ablation of an exophytic left renal tumour (histologically demonstrated clear cell carcinoma) located
on the lower pole: a: localising CT acquisition with injection of contrast agent, in an axial slice; b: radiofrequency treatment using a
deployable antenna guide: post-injection axial CT scan; c: immediate postoperative control shows classic changes (gas, interstitial oedema,
perirenal inﬁltration); d: MRI control in an axial slice, 2 months after the procedure, showing the typical sequelae of post-ablation necrotic-
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taemorrhagic changes as a T2 hyposignal; e: spontaneous T1 hyp
nhancement following injection of gadolinium chelate on the cont
nformative  and  representative  of  the  contribution  of  the
echnique  to  oncological  control,  with  values  between  90
nd  100%  [17,21,22,25,26].  In  a  small  series,  comparing  37
atients  treated  by  partial  nephrectomy  with  40  patients
reated  by  percutaneous  or  laparoscopic  radiofrequency,
tern  found  no  signiﬁcant  difference  in  recurrence-free  sur-
ival  at  3  years  for  T1a  tumours,  with  respective  levels  of
5.8%  and  93.4%  [27]. In  radiofrequency  thermal  ablation,
he  size  and  sinus  extension  of  the  tumour  to  be  treated
an  increase  the  risk  of  technical  failure  [25]. In  a  series
f  104  patients  and  125  tumours,  Zagoria  was  able  to  treat
ll  cancers  measuring  less  than  3.7  cm  completely.  The  sur-
ival  rate  without  recurrence  fell  to  only  47%  for  tumours
ver  3.7  cm  in  size.  For  tumours  larger  than  3.6  cm,  this
uthor  described  a  risk  of  recurrence  increased  by  a  factor
f  2.19  for  each  additional  centimetre.  The  recurrence-free
urvival  rate  was  not  however  inﬂuenced  by  sex,  the  side
r  cranio-caudal  topography  of  the  tumour.  Zagoria  found
o  signiﬁcant  difference  whether  the  site  of  the  lesion  was
xophytic,  parenchymal,  central  or  mixed  [19]. Gervais,  in series  of  85  patients  and  100  tumours,  identiﬁed  tumour
ize  of  less  than  3  cm  and  a  non-central  location  as  inde-
endent  factors  of  primary  efﬁcacy.  Only  the  non-central
ite  of  lesions  is  described  as  an  independent  factor  of
a
o
b
inal on the MRI control in an axial slice at the same level; f: no
RI in an axial slice.
econdary  efﬁcacy.  Gervais  emphasised  that  the  choice  of
 size  limit  for  treatment  is  not  unequivocal.  In  his  series,  a
ut-off  at  4  cm  produced  treatment  that  was  90%  complete,
hile  excluding  15%  of  patients  who  could  have  beneﬁted
rom  effective  treatment.  A  cut-off  at  5.8  cm  would  mean
9%  of  patients  could  be  treated  completely,  but  with  a
hort-term  success  rate  of  63%  [17]. At  present,  these  results
eed  to  be  conﬁrmed  in  series  with  long-term  follow-up.
ryotherapy
he  ﬁrst  use  of  cryoablation  to  treat  renal  tumours  (Fig.  2)
as  reported  in  1995  [28]  and  was  initially  performed  by
aparoscopy  (65%)  [29]. The  percutaneous  approach  has
nly  developed  recently  owing  to  a  reduction  in  the  size
f  cryoprobes.  The  basis  of  this  ablation  technique  is  the
estruction  of  tumour  cells  using  freeze/thaw  cycles.  Dur-
ng  the  freeze  part  of  the  cycle,  the  formation  of  ice  crystals
enatures  the  intracellular  proteins,  breaks  up  cell  struc-
ures  and  modiﬁes  cell  membrane  function.  Subsequently,
fter  increasing  the  intracellular  osmotic  pressure,  an  inﬂow
f  water  occurs  during  thawing  resulting  in  the  tumour  cells
ursting  [30]. A  major  advantage  of  cryoablation  is  the  abil-
ty  to  monitor  the  ablation  zone  in  real  time  [31,32]  by
Radiologically-guided  thermal  ablation  of  renal  tumours  249
Figure 2. Cryoablation of a left renal papillary tumour in an anterior exophytic location, near the tail of the pancreas, in a patient with
a history of contralateral nephrectomy: a: left anterior renal tumour in a CT axial slice with injection (arterial phase); b: renal mass in a
sagittal slice with injection (cortical phase); c: cryotherapy with visualisation of a needle and dissection with CO2 to displace the digestives
structures: axial CT without injection; d: cryotherapy: the 3 cryoprobes and the CO2 dissection are visible on this oblique coronal CT scan; e:
control after the procedure, in an axial slice comparable to ﬁgure c; f: control in an oblique coronal slice showing the hypodense extension of
the ice after removal of the cryoprobes, comparable to ﬁgure d; g: MRI control at 6 months showing the post-ablation necrotic-haemorrhagic
changes, with a typical T2 hyposignal halo in this axial slice; h: absence of enhancement on this T1-weighted axial MRI with injection.
250  F.  Cornelis  et  al.
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sigure 2. (Continued ).
igure 3. Microwave thermal ablation of an upper polar tumour (clear
f contrast agent in the arterial phase; b: comparative coronal slice wit
agittal slice, with injection of contrast agent in the arterial phase: d:
ass: CT axial scan without injection; e: applicator positioned in the cen
njection (arterial phase) at 6 months, showing neither recurrence nor an
lice. (Acknowledgements to Dr Régis Hubrecht, centre hospitalier de Pa cell carcinoma) of the left kidney: a: CT axial slice with injection
h injection of contrast agent in the arterial phase; c: comparative
 treatment with microwaves, with an applicator positioned in the
tre of the lesion on this coronal scan; f: control CT axial scan, with
y remnant; g: control CT scan with injection: comparative coronal
u, France.)
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visualising  the  physical  changes  caused  by  freezing,  whether
using  CT,  MRI  or  ultrasound.  This  is  particularly  useful  when
the  lesion  to  be  treated  is  close  to  sensitive  organs  or  struc-
tures.  Another  advantage  is  that  there  is  no  denaturing  of
protein,  as  in  hyperthermic  treatment,  in  the  architecture
of  supporting  tissues,  particularly  urothelial  tissue,  which
is  therefore  conserved.  In  Kunkle’s  meta-analysis  [29], the
primary  efﬁcacy  of  cryotherapy  was  better  than  that  of  RF
treatment,  with  a  reoperation  rate  of  8.5%  for  RF  versus
1.3%  for  cryotherapy  (P  <  0.0001).  The  local  tumour  progres-
sion  rate  was  signiﬁcantly  higher  for  RF  (12.9%  as  against
5.2%  (P  <  0.0001)  for  cryoablation.  Moreover,  the  frequency
of  metastases  was  reported  to  be  lower  for  cryoablation
(1.0%)  than  for  RF  (2.5%,  P  =  0.06)  during  monitoring.
Microwave thermal ablation
Microwave  ablation  is  a  thermal  ablation  technique  that  is
currently  used  for  the  treatment  of  hepatocellular  carci-
noma  or  lung  carcinoma  [33], but  its  use  in  kidney  cancer  is
still  being  evaluated  (Fig.  3).  The  potential  beneﬁt  of  this
technique  [34]  is  ablation  that  is  not  limited  by  desiccation,
carbonisation  or  thermal  convection  [35]. As  a  consequence,
the  temperature  obtained  is  high,  and  can  result  in  a  larger
ablation  zone  being  treated  in  less  time.
[
e
(
oAfter  adjusting  the  technique,  Clark  et  al.  [36]  gave  10
atients  microwave  treatment  before  nephrectomy.  Histo-
ogical  analysis  showed  uniform  cell  death  in  the  ablation
one.  Liang  et  al.  [33]  recently  reported  the  results  of  a
easibility  study  in  which  12  patients  were  treated  with  no
emnant  or  recurrence  at  a  mean  follow-up  of  11  months.
arraﬁello  et  al.  [37]  also  performed  12  successful  proce-
ures,  with  a  mean  follow-up  of  6  months  [3—14]. It  is
owever  necessary  to  analyse  complications,  tolerance  and
fﬁcacy  in  the  medium  term.
ocused ultrasound ablation
any  experimental  studies  have  been  performed  on  the  kid-
ey  in  animals  (Fig.  4).  In  contrast,  clinical  applications  are
till  in  the  very  early  stages  and  no  recent  review  of  clinical
tudies  has  been  published.  Nevertheless,  such  applications
ere  initiated  very  early  on  because  of  the  totally  non-
nvasive  character  of  this  technique.  In  the  1990s,  a  study
38]  including  eight  patients  treated  pre-operatively  showed
hermal  ablation  lesions.  More  recently,  Marberger  et  al.
39]  treated  16  patients,  again  pre-operatively,  but  consid-
rably  underestimating  the  volume  of  the  lesion  induced
only  15  to  35%  of  the  target  volume).  The  results  were
nly  analysed  for  the  10  of  the  13  patients  treated  by
252  F.  Cornelis  et  al.
Figure 4. Focused ultrasound thermal ablation performed during a large animal experimental procedure: a: positioning the transducer,
with the red triangle showing the focusing cone. The transducer is visible at the bottom of the image (arrow), on a T1-weighted axial MR
image; b: determination of the focal point (arrow) on the T1-weighted sagittal MR image; c: temperature MRI (proton resonance frequency
(PRF) method) controlling heating at the focal point in real time, merged with a sagittal T1-weighted gradient echo MR image; d: thermal
dose mapping merged with a sagittal T1 gradient echo MR image; e: control following ablation at the same level by T1-weighted MRI (sagittal
slice) after injection, showing the ablation area which is not enhanced; f: control T2-weighted TSE MRI (sagittal slice) showing necrotic-
haemorrhagic changes as a T2 hyposignal; g: apparent diffusion coefﬁcient (ADC) mapping in a sagittal slice showing diffusion restriction of
the treated area.
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Figure 5. Digestive complications of the ablation procedures: a: left renal mass on the only kidney (arrow) in a patient with a history of
ipsilateral ablation (dotted arrow); b: radiofrequency with deployable needle: CT axial scan without injection; c: enhancement within the
ablation zone (hyposignal), corresponding to leakage of excreted contrast medium on this T1-weighted MRI with injection and subtraction;
d: ﬁstulation of the colon shown by a hypersignal in the intestinal tract in the later phases after injection, in T1-weighting with subtraction.
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Wu  et  al.  [40]  who  were  being  given  palliative  treat-
ment.  In  the  Oxford  group  series,  complete  treatment  was
demonstrated,  in  ﬁve  cases  out  of  10  [41], only  when  the
tumour  was  completely  accessible  via  the  subcostal  route,
which  further  emphasises  the  problem  of  acoustic  inter-
faces.  These  issues  have  been  discussed  in  a  recent  general
review  [42]. This  author  also  highlights  the  problems  of
positioning  the  focus  during  respiration,  since,  even  if  the
shots  are  made  during  apnoea,  each  shot  must  be  reposi-
tioned  relative  to  the  others  to  the  nearest  millimetre,  to
avoid  leaving  intervals  of  untreated  tissue.  Technical  solu-
tions  have  nevertheless  recently  been  proposed  [43—45]  to
improve  control  of  the  energy  applied,  thus  opening  up  new
prospects.
Complications
In  addition  to  its  oncological  efﬁcacy,  the  low  morbidity  of
percutaneous  thermal  ablation  is  a  major  asset  for  the  treat-
ment  of  kidney  cancer  in  patients  who  are  poor  candidates
for  surgery  because  of  their  comorbidities  [46]. The  rates  of
complications  for  thermal  ablations  reported  in  the  litera-
ture  are  very  variable,  between  4  and  37%,  because  of  an
i
a
1
ts for this patient.
bsence  of  standardisation  in  grading  the  side  effects  [47],
hich  have  mainly  been  described  for  radiofrequency  and
ryotherapy  techniques.
leeding
 perirenal  haematoma  is  the  most  common  complication,
n  0  to  30%  of  cases  depending  on  the  series  [17,48,49],
nd  particularly  concerns  procedures  performed  using
ryotherapy,  even  if  more  evidence  must  be  obtained  from
arge  series.  These  haemorrhages  are  usually  minor  and
symptomatic  and  do  not  justify  special  monitoring.  The
isk  of  major  bleeding  with  a  fall  in  erythrocyte  count  and
he  need  for  transfusion  is  rare,  in  the  order  of  0  to  2%  in
he  literature  [17,19]. The  risk  of  bleeding  is  increased  in
atients  receiving  non-interrupted  antiplatelet  therapy  or  if
he  lesion  is  close  to  a  vascular  pedicle.  It  can  be  prevented
y  good  vascular  screening  before  the  procedure  and  with
apid,  optimal  positioning  of  the  electrode.  Gross  haema-
uria,  at  the  end  of  the  procedure,  is  a  rare  event  occurring
n  0  to  2.5%  of  cases  [50]. This  should  not  be  considered  an
larm  signal,  especially  if  the  urine  gradually  clears  within
2  hours  [51]; this  risk  will  be  greater  in  the  case  of  a  central
umour  [51,52].
254  F.  Cornelis  et  al.
Figure 6. Urinary tract complications after thermal ablation in two different patients: a: radiofrequency thermal ablation of a left renal
mass on a solitary kidney: CT axial slice with injection; b: procedure complicated by a retroperitoneal urinoma from calyceal leakage, easily
identiﬁed on late CT acquisitions; c: radiofrequency thermal ablation of a central right renal tumour: late CT axial slice with injection; d:
p tiﬁed
P
T
d
o
w
p
t
P
T
c
n
i
a
R
T
t
r
H
v
r
o
i
r
a
r
a
c
t
t
a
t
d
T
A
t
t
w
a
erocedure complicated by stenosis of the upper urinary tract, iden
ain and neuromuscular weakness
his  is  usually  temporary  [19]  and  uncommon,  being
escribed  in  4.5%  of  cases  [20,26],  and  results  from  lesions
f  the  lumbar  plexus,  subcostal  or  genitofemoral  nerves,
hich  pass  close  to  the  lower  pole  of  the  kidney  and  the
soas  muscle  [9,51,53].  Posterior  approaches  passing  close
o  the  anterior  surface  of  the  psoas  muscle  are  most  at  risk.
neumothorax
he  incidence  of  pneumothorax  is  1  to  2%  [19,50]. In  most
ases,  these  pneumothorax  are  minor,  well  tolerated  and  do
ot  justify  drainage  [54]. Approach  through  a  pleural  recess
s  sometimes  anticipated  and  unavoidable  for  tumours  which
re  difﬁcult  to  access  [54].
isk factors
he  rate  of  major  complications  is  generally  in  the  range  of  0
o  6%  [7,17—19,25]. In  a  meta-analysis  of  minimally  invasive
adiofrequency  and  percutaneous  cryotherapy  procedures,
ui  et  al.  reported  3.1%  of  serious  complications  [5].  The
arious  studies  in  the  literature  describe  variable  statistical
atios  between  the  different  tumour  parameters  and  the  risk
s
s
c
m by T2-weighted MRI (axial slice).
f major  complications,  which  can  be  explained  by  their  low
ncidence.  In  a  series  of  71  patients  with  87  tumours  and  a
ate  of  major  complications  of  4.6%,  Velti  et  al.  found  that
n  exophytic  location  played  a  protective  role  [25]. Zago-
ia  et  al.,  in  a  series  of  104  patients  with  125  tumours  and
 rate  of  major  complications  of  2.9%,  did  not  report  any
hanges  in  the  rate  of  complications  related  to  the  loca-
ion  of  the  tumour,  the  patient’s  sex  or  even  the  size  of
he  lesion  [19]. In  a  series  of  24  patients  with  32  tumours
nd  a rate  of  major  complications  of  16.6%,  Weizer  found
hat  this  rate  increased  when  several  tumours  were  treated
uring  the  same  session  [55].
hermal lesions of the digestive tract
 major  complication  to  be  feared,  and  speciﬁc  to  hyper-
hermic  ablation  treatments,  is  the  result  of  thermal  injury
o  adjacent  organs,  including  the  digestive  tract.  It  is  rare,
ith  a  mean  of  between  0  and  1%  in  the  series  [17,20,48],
nd  can  appear  with  a  free  interval  of  several  days,  threat-
ning  the  life  of  the  patient  and  requiring  emergency
urgical  management  because  of  the  risk  of  perforation  and
eptic  complications.  The  colon,  particularly  exposed  in  the
ase  of  upper  pole  and  anterior  tumours  [55], seems  to  be
ost  at  risk  of  thermal  injury  (Fig.  5).  The  stomach,  probably
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Figure 7. Infectious complications of thermal ablation: a: radiofrequency ablation of a left lower pole renal mass: pre-treatment coronal
T1-weighted MRI with injection; b: secondary infection of the ablation zone: CT coronal slice with injection; c: control examination 2 months
after antibiotic treatment: T2-weighted MRI (axial slice); d: control examination 2 months after antibiotic treatment: T1-weighted MRI with
injection of contrast agent (comparative axial slice); e: control examination 6 months after antibiotic treatment: T2-weighted MRI (axial
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Islice) showing regression of the infected ablation zone; f: control e
injection of contrast agent (comparative axial slice).
because  of  the  thickness  of  its  wall,  and  the  small  intes-
tine,  because  of  its  mobility,  are  less  sensitive  to  thermal
damage  [51]. Preventing  thermal  injury  to  adjacent  organs
is  based  on  the  presence  of  a  fatty  safety  area  of  at  least
5  mm  [52]  which  can  be  artiﬁcially  increased  by  reposition-
ing  the  patient  or  using  hydrodissection  (exclusively  glucose
or  sterile  water)  and/or  CO2  dissection  [56,57].  In  contrast,
thermal  damage  to  the  liver  and  spleen  is  often  minor  and
of  no  consequence  for  the  patient  [51].
Lesions of the urinary tract
The  upper  urinary  tract  is  particularly  exposed  during
treatment  of  central  tumours  by  hyperthermic  ablation
techniques  (Fig.  6),  in  contrast  to  cryotherapy,  but  these
complications  are  rare  [51], less  than  4%  in  the  litera-
ture  [17,19,50,55]. In  the  acute  phase,  a  ureteral  injury
may  appear  as  a  perforation  with  formation  of  a  urinoma.
The  symptoms  may  appear  several  months  later  as  ureteral
stenosis,  with  the  risk  of  recurrent  urinary  tract  infections,
D
(
i
[nation 6 months after antibiotic treatment: T1-weighted MRI with
ydronephrosis  and  impaired  renal  function,  necessitating
tting  of  a double  J  stent,  a  nephrostomy  or  a  ureteral
tent  [58]. It  is  necessary  to  prevent  these  complications,
articularly  for  central  and  lower  pole  tumours,  where  the
inimum  safety  distance  from  the  ureter  is  less  than  15  mm,
nd  often  requires  the  use  of  cryotherapy.  However,  pre-
perative  ﬁtting  of  a  ureteral  catheter  with  per-operative
yelocaliceal  irrigation  using  a  non-ionic  5%  glucose/sterile
ater  mixture  [58]  which  is  not  modiﬁed  by  the  RF  waves
an  be  discussed.  The  corollary  to  preventing  pyeloureteral
hermal  injury  by  this  way  is  the  possible  decrease  in
he  efﬁcacy  of  the  thermal  ablation  by  the  ‘‘heat-sink
ffect’’.
nfectionespite  taking  aseptic  measures,  the  risk  of  infection
Fig.  7)  is  not  negligible,  being  in  the  order  of  0  to  2%
n  the  series  [7,25]. Diabetes  increases  the  risk  of  sepsis
51].
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Figure 8. Typical appearance in T1-weighted MRI of necrotic-haemorrhagic post-ablation changes: a: spontaneous T1 hypersignal (coronal
slice); b: no detectable enhancement after injection in the arterial phase (axial slice); c: no detectable enhancement after injection
in the cortico-medullary phase (axial slice); d: no enhancement on the subtracted sequence (coronal slice). Subtraction sequences are
recommended to detect remnants and in situ recurrences.
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cumour dissemination
tudied  in  radiofrequency  ablation,  tumour  dissemination
long  the  applicator  path  is  exceptional,  as  only  two  cases
ave  been  reported  in  the  literature  [59]. To  minimise  this
isk,  the  electrode  must  be  positioned  optimally  in  a direct
ath,  and  the  path  of  the  needle  should  be  treated  at  the  end
f  the  procedure;  this  can  also  reduce  the  risk  of  bleeding
51].
urveillance and follow-up imagingt  is  essential  for  patients  to  be  monitored  for  remnants  or
ecurrences.  Although  a  biopsy  is  the  gold  standard,  it  is
n  invasive  procedure,  the  usefulness  of  which  is  controver-
ial.
t
c
t
normal appearance in imaging
onitoring  by  imaging  is  nowadays  essential.  The  appear-
nce  of  an  ablation  site  evolves  with  time  in  a  normal  and
elatively  predictable  way.  Several  changes  occur,  particu-
arly  the  size  of  the  site:  a  clear  increase  in  the  volume
f  the  site  treated  by  heat  ablation  appears  early  in  the
ollowing  week  and  the  ﬁrst  2  months  after  the  proce-
ure,  particularly  for  small  tumours  of  less  than  3  cm3
60]. Then,  the  scar  volume  gradually  decreases  over  1  to
 years.
In  a  CT  scan,  the  density  of  the  treated  area,  the  site  of
oagulation  necrosis,  is  and  remains  spontaneously  denser
han  the  adjacent  renal  parenchyma.  No  contrast  uptake
an  be  identiﬁed.  However,  in  a  series  of  36  radiofrequency-
reated  tumours,  Javadi  described  signiﬁcant  homoge-
eous  enhancement,  greater  than  10  HU,  visible  in  the
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Figure 9. Typical appearance in a T2-weighted MRI of necrotic-haemorrhagic post-ablation changes: a: exophytic right renal tumour in
T1-weighted MRI with injection (axial slice); b: radiofrequency thermal ablation with deployable needle: CT axial scan without injection; c:
absence of contrast uptake after injection in the cortical phase in the 2-month control on MRI subtracted sequences; d: absence of contrast
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ablation zone, associated with the zone’s peripheral halo, includin
borders during this axial T2 MRI follow-up; f: coronal T2-weighted h
parenchymal  phase,  on  a  control  on  D0  of  the  radiofrequency
sites,  which  improved  over  time  in  78%  cases  [61].
In  MRI,  the  treated  site  is  heterogeneous,  generally  with  a
T1  hypersignal  and  a  T2  hyposignal  without  contrast  uptake
(Figs.  8  and  9).  A  thin  ring  of  peripheral  enhancement  can
be  seen  on  late  acquisitions  throughout  follow-up,  with
no  suspicious  character,  probably  related  to  inﬂammatory
changes.
In  both  CT  and  MRI,  inﬁltration  of  peripheral  fat  is  almost
systematic,  especially  with  exophytic  tumours  [53]. A  spon-
taneously  dense  peripheral  halo  with  a  T1  hyposignal  has
been  reported  in  nearly  75%  of  cases;  it  appears  during  the
ﬁrst  months  and  often  persists  [62]. Fat  invagination  into  the
scar  is  less  common  and  occurs  later  [60]. MRI  has  no  partic-
ular  advantage  over  CT  apart  from  not  requiring  injection  of
an  iodinated  contrast  agent;  it  should  therefore  be  preferred
in  cases  of  renal  impairment.
As  for  cryotherapy,  there  is  no  precise  description  of  the
ablation  zone,  the  volume  of  which  tends  to  decrease  over
time;  MRI  shows  a  clear  T2  hyposignal  ring  [63].Tumour residue and local recurrence
The  presence  of  focal  nodular  contrast  enhancement  is  still
the  only  validated  marker  of  living  residual  or  recurrent
e
antrol on MRI subtracted sequences; e: typical hyposignal from the
 tumour and surrounding treated tissue, deﬁning the therapeutic
ignal from the ablation zone and peripheral halo.
umour  tissue  and  involves  acquisition  ﬁrst  without  injection
f  contrast  agent  and  then  with  this  injection.
In  the  CT  scan,  enhancement  is  evaluated  qualita-
ively  and  quantitatively.  Any  contrast  enhancement  of  the
adiofrequency  site  of  more  than  10  HU  [19]  or  15  HU  [64]
ust  be  considered  signiﬁcant,  suggestive  of  a  residual  or
ecurrent  local  tumour.  Any  complication  due  to  local  infec-
ion  may  make  this  analysis  difﬁcult.
In  MRI,  because  of  the  T1  hypersignal  from  the  ablation
ite,  subtraction  techniques  must  be  widely  used  to  detect
r  eliminate  focal  enhancement.  Quantitatively,  enhance-
ent  is  considered  signiﬁcant  if  it  exceeds  15%  on  the
ynamic  sequence  [19,65].
Some  authors  have  evaluated  the  feasibility  of  contrast-
nhanced  ultrasound  (SonoVue®,  Bracco,  Milan,  Italy)  during
onitoring,  instead  of  CT  or  MRI  [66], with  a possible  limit
or  hypovascularised  and/or  deep  tumours  for  which  this
xamination  may  be  found  wanting  as  regards  detecting
iving  tumour  tissue.  This  technique  is  to  be  preferred  in
atients  with  severe  renal  impairment,  in  whom  injection
f  iodinated  or  gadolinium  chelate  contrast  agent  is  con-
raindicated.There  is  no  recommendation  on  follow-up  in  terms  of
xamination  dates,  but  there  is  some  consensus  in  the  liter-
ture.  Follow-up  is  generally  frequent  during  the  ﬁrst  year
258  F.  Cornelis  et  al.
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Cigure 10. CT axial slice with injection in the cortical phase. A
adiofrequency needle positioned within the tumour (b). Axial T2-
uring follow-up.
ollowing  the  ablation  [67], with  three  to  four  examinations
radually  more  widely  spaced:  at  2,  6  and  12  months  or  at
,  3,  6  and  12  months.  An  annual  follow-up  is  then  recom-
ended  for  5  years  or  even  longer.
ephron-sparing measures
paring  the  kidney  is  the  objective  at  the  forefront  of  RCC
anagement.  Besides  in  familial  diseases,  such  as  von  Hippel
indau  disease,  in  which  the  high  frequency  of  synchronous
nd  metachronous  cancer  sites  requires  multiple  treatment
ith  progressive  reduction  in  kidney  reserves,  it  has  been
hown  that  progression  towards  chronic  renal  disease  is  asso-
iated  with  increased  mortality  [68].
Many  studies  agree  in  demonstrating  the  absence  of  sig-
iﬁcant  impairment  of  renal  function  at  1  month  and  1
ear  for  patients  treated  for  a  single  tumour  [22,25,69].
n  a  series  of  242  patients,  Lucas  observed  preservation  of
enal  function  after  radiofrequency  and  partial  nephrectomy
hich  was  signiﬁcantly  higher  than  for  total  nephrectomy
urgical  techniques,  with  a  rate  without  appearance  of
hronic  renal  impairment  after  3  years  of  95.2%,  70.7%  and
9.9%  respectively  [70].
Raman  compared  47  patients  who  had  had  a  solitary
idney  treated  by  radiofrequency  with  42  treated  by  open
A
d
u
cCT scan after injection in the late phase (a) with the deployable
hted (c) and T1-weighted MRI with injection and subtraction (d),
artial  nephrectomy,  with  mean  tumour  sizes  of  2.8  and
.9  cm  respectively,  mean  renal  function  of  46.5  mL/min  and
5.9  mL/min  respectively  and  mean  follow-up  of  18.1  and  30
onths.  Decline  in  renal  function  was  signiﬁcantly  higher  in
atients  treated  with  conservative  surgery  than  in  patients
reated  by  radiofrequency,  both  soon  after  the  procedure
15.8%  versus  7.1%),  at  12  months  (24.5%  versus  10.4%)  and
t  the  last  follow-up  (28.6%  versus  11.4%;  P  <  0.001).  The
roportion  of  patients  who,  during  follow-up,  developed
oderate  (CrCl  <  60  mL/min)  and  severe  (CrCl  <  30  mL/min)
enal  impairment  was  0%  and  7%  respectively  for  patients
reated  with  radiofrequency  as  against  35%  and  17%  where
reatment  had  been  surgical  [71].
A  recent  study  [53], reviewing  24  thermal  ablations
radiofrequency  and  cryoablation)  on  kidney,  transplants
howed  no  change  in  renal  function  following  the  proce-
ures.
onclusionpart  from  the  need  for  large-scale  validation  of  newly
eveloping  techniques  such  as  microwaves  and  focused
ltrasound,  the  long-term  results  of  radiofrequency  and
ryotherapy  ablations  need  to  be  conﬁrmed.  Nevertheless,
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given  the  low  morbidity  of  these  techniques  and  the  excel-
lent  oncological  efﬁcacy  reported  in  the  management  of
kidney  tumours  of  less  than  4  cm,  enlarging  the  indications
to  a  wider  population  can  be  envisaged.  Prospective  studies
comparing  thermal  ablation  with  the  reference  treatment,
which  is  still  surgery,  must  now  be  undertaken.
TAKE-HOME  MESSAGES
General  points  on  the  thermal  ablation  of  renal  tumours
• Thermal  ablation  techniques  can  be  proposed  for
renal  tumours  as  an  alternative  to  surgery.
• These  techniques  are  effective,  with  results
comparable  to  those  of  partial  nephrectomy,  and
they  preserve  kidney  capital.
• Morbidity  is  low  if  precautionary  rules  are  followed,
particularly  concerning  adjacent  organs  (the
digestive  or  urinary  tract).
• Radiofrequency  thermal  ablation  is  simple,  effective
and  economical.
• Cryotherapy  allows  the  ablation  zone  to  be
controlled  and  appears  to  be  particularly  useful  for
treating  central  tumours,  as  it  does  not  damage  the
supporting  urothelial  tissue.
• Microwave  ablation  allows  larger  ablation  zones  to
be  treated.
• The  use  of  focused  ultrasound  is  still  to  be  deﬁned.
Follow-up  after  thermal  ablation
• Regular  follow-up  is  necessary  (at  2,  6  and  12  months
during  the  ﬁrst  year).
• This  may  be  with  ultrasound,  CT  or  MRI.
• Injection  of  a  contrast  agent  is  required  to  detect
remnants  or  recurrences  that  are  hypervascularised.
• Interpretation  may  be  hindered  by  necrotic-
haemorrhagic  changes  that  give  a  T1  hypersignal
and  T2  hyposignal  in  MRI,  and  are  spontaneously
dense  in  a  CT  scan.  The  T1  hypersignal  requires
subtraction  sequences  to  be  undertaken  after
injection  of  a  contrast  agent  in  order  to  detect  early
contrast  uptake.
Clinical case
This  86-year-old  woman  presented  a  32  mm  left  renal
tumour  (Fuhrman  2  clear  cell  carcinoma)  (Fig.  10a).  Con-
sidering  the  age  and  general  condition  of  the  patient,
radiofrequency  thermal  ablation  was  decided  in  a  multidis-
ciplinary  meeting.
The  procedure  was  performed  under  CT  guidance  and
general  anaesthesia  (Fig.  10b)  without  complication.  The
patient  was  reassessed  by  MRI  some  time  after  the  procedure
(Fig.  10c:  1,  2).Questions
1.  What  follow-up  should  be  proposed  after  this  thermal
treatment?259
. Is  an  injection  at  the  time  of  the  examination  needed  for
this  surveillance?
. What  is  your  diagnosis  and  what  management,  if  neces-
sary,  do  you  recommend?
nswers
.  Follow-up  using  imaging  should  be  offered  systemati-
cally.  The  technique  used  must  be  adapted  to  each  case,
using  ultrasound,  CT  or  MRI  particularly  depending  on
the  contraindications  (especially  renal  impairment).  Ide-
ally,  the  examinations  will  be  performed  at  2,  6  and  12
months  during  the  ﬁrst  year,  then  annually  if  there  is  no
recurrence.
. Injection  of  a  contrast  agent  is  essential  for  identifying  a
residual  tumour  or  an  in  situ  recurrence,  because  images
contain  artefacts  due  to  necrotic-  haemorrhagic  changes
secondary  to  thermal  ablation.
. The  control  MRI  shows  a  T2  hypersignal  and  above  all
peripheral  uptake  of  contrast,  corresponding  to  tumour
remnants,  and  not  recurrence,  for  this  was  detected  dur-
ing  the  ﬁrst  follow-up  examination  and  was  secondary
to  incomplete  treatment  (due  to  the  size  of  the  lesion
or  the  technique  used).  Primary  efﬁcacy  was  not  good,
therefore,  in  this  case.  A  new  procedure  had  to  be  pro-
posed  as  a  ﬁrst  course  of  action,  in  order  to  complete
the  treatment,  taking  into  account  the  limits  of  the
ﬁrst  technique  used.  Cryotherapy  treatment  was  pro-
posed  and  performed  in  this  patient.  Given  the  efﬁcacy
of  this  second  procedure  on  the  control  examinations,
the  secondary  efﬁcacy  of  the  thermal  treatment  over-
all  (radiofrequency  then  cryotherapy)  was,  in  the  end,
good.
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